Shots: InveniAI is eligible to receive up to $200M/ program as up front, development, and commercial milestones along with royalties The collaboration integrates InveniAI’s AI platform AlphaMeld to identify, evaluate, optimize novel targets with Shionogi’s expertise in developing and commercializing therapeutic modalities Shionogi will synthesize… Read More »InveniAI Collaborates with Shionogi on AI-Based Drug Discovery
Plant-based drug discovery may be tens of thousands of years old, but in 2021, it feels exciting, rich, and full of potential. Companies are rapidly building scalable databases with hundreds of thousands of unique chemicals and their links to biological signatures.
Relay Therapeutics has its own technology that applies artificial intelligence and machine learning techniques to drug discovery. Its $85 million acquisition of ZebiAI gives it another technology that applies ML to DNA-encoded libraries and predicts the small molecules with the potential to drug proteins.
The first quarter of 2021 has been one of investor optimism as the vaccine rollout continues ahead of expectations and economic activity begins to accelerate in response. Within the Health IT industry, the already strong investment and M&A trends seen in 2020 have only accelerated. Over the… Read More »Q1 2021 Health IT/Digital Health PC/VE, M&A, IPOs/ SPACs Activity
Exscientia was the first company to start human trials of a new drug designed using artificial intelligence (AI) last year, and now says it has started testing of the first AI candidate for immuno-oncology. Oxford, UK-based Exscientia has been working with German biotech Evotec on… Read More »Exscientia starts trials of first AI-derived cancer immunotherapy
There’s a new kid on the block among companies using artificial intelligence in drug discovery, after 1910 Genetics launched today with $26 million in financing. The Cambridge, Massachusetts-based startup claims it is the only biotech launched so far that will use AI to design both… Read More »AI drug discovery player 1910 Genetics debuts with $26m war chest
Shots: Evotec to receive research funding and will be eligible for $160M/program as discovery, pre/ clinical, a commercial milestone along with royalties on sales of product emerges from the collaboration The collaboration will utilize Evotec’s RNA targeting platform to identify RNA sequences to target with… Read More »Takeda Collaborates with Evotec on RNA Targeting Drug Development
New biotech Antiverse has raised seed funding of £1.4 million ($2 million) to develop its artificial intelligence-based platform for discovering therapeutic antibodies. The Cardiff, Wales startup is combining machine learning and phage display techniques to model antibody-antigen binding and says it can cut the time… Read More »Welsh startup Antiverse raises $2m for antibody discovery toolkit
Canada’s Valence Discovery has joined a University of Montreal-led project to try to find new drugs to treat the involuntary movement complications that can accompany treatments for Parkinson’s disease. The go-to treatment for the five million people worldwide with Parkinson’s is levodopa, which replaces the… Read More »AI drug discovery firm Valence joins Parkinson’s disease push
What You Should Know: – Exscientia, leading AI drug discovery company, today announced that it completed its $100 million Series C financing round, with a further $30 million investment from Blackrock. – This new capital, which will be used to support Exscientia’s platform development and… Read More »Exscientia Secures $100M To Expand AI Drug Discovery Platform
Roivant Sciences is expanding its drug discovery and design capabilities via a stock deal to acquire Silicon Therapeutics. The Boston startup uses physics-based modeling to simulate proteins and the small molecules that bind to them.
Shots: The collaboration will merge Microsoft’s computational services, cloud and AI with UCB’s drug discovery and development capabilities The companies intend to discover and develop medicines for people living with severe diseases in immunology and neurology. The collaboration follows UCB and Microsoft’s collaboration around COVID-19… Read More »UCB Collaborates with Microsoft to Accelerate Drug Discovery and Development
What You Should Know: – Global biopharma company UCB and Microsoft announced today a new, multi-year strategic collaboration to advance UCB’s digital transformation, change the way care is delivered, and accelerate better outcomes for people living with severe diseases. – The partnership builds on the companies’ joint… Read More »Microsoft, UCB Launch Collaboration to Accelerate Drug Discovery and Development
Medical charity Alzheimer’s Research UK has teamed up with artificial intelligence specialist Exscientia to find new drug treatments for the devastating neurodegenerative disease. The alliance will see Exscientia work with the charity’s Oxford Drug Discovery Institute (ODDI) to find therapeutics that target the neuroinflammation associated… Read More »Alzheimer’s Research UK starts AI-based drug hunt with Exscientia
Shots: Evotec to receive milestones, royalties, and a founding equity stake in all Related Sciences assets developed under the collaboration Evotec and Related Sciences will jointly discover & develop a multitude of therapeutic approaches with IND filings over a multi-year period. The partnership will combine… Read More »Evotec Collaborates with Related Sciences for Drug Discovery and Development
Drug discovery is a complex process which involves significant utilization of time and resources. As per several sources, on an average, the entire drug development process (from initial proof-of-concept to commercial launch) takes around 10-15 years and capital investments worth USD 4-10 billion to develop… Read More »Artificial Intelligence in Drug Discovery – Could help Reduce Significant Capital and Time Required
Artificial Intelligence have demonstrated intelligent behavior through their ability to learn, communicate with its users and solve complex problems using highly sophisticated algorithms. AI-driven technologies have continued to evolve rapidly, with several industries increasingly deploying such solutions across key aspects of value chain. Furthermore, AI… Read More »Advancing Healthcare Delivery via Artificial Intelligence
Roche Collaborate with Cambridge Quantum Computing to Develop Quantum Algorithm for Drug Discovery and Development
Shots: CQC collaborates with Roche to design and implement noisy-intermediate-scale-quantum (NISQ) algorithms for early-stage drug discovery and development The collaboration will employ CQC’s quantum chemistry platform ‘EUMEN’, to augment the Roche’s AD research efforts The multi-year collaboration will combine the expertise of both CQC and… Read More »Roche Collaborate with Cambridge Quantum Computing to Develop Quantum Algorithm for Drug Discovery and Development
Elsevier, the data analytics business specialized in science and health, and Heel, a pharmaceutical company specialized in developing and manufacturing medicines made from natural ingredients, have recently completed a series of research projects with a focus on improving exploratory preclinical studies. “We at Heel are… Read More »Elsevier to Work with Heel for Mechanism-based Drug Action Discovery
As we close out the year, we asked several healthcare executives to share their predictions and trends for 2021. Kimberly Powell, Vice President & General Manager, NVIDIA Healthcare Federated Learning: The clinical community will increase their use of federated learning approaches to build robust AI models across various… Read More »30 Executives Share Top Healthcare Predictions & Trends to Watch in 2021
AbCellera Biologics has been in the spotlight since coming up with Eli Lilly’s COVID-19 antibody drug bamlanivimab, and looks set to capitalise on that exposure with a sizeable initial public offering. The Vancouver, Canada-headquartered biotech – which has been bankrolled in part by billionaire entrepreneur… Read More »AI drug discovery biotech AbCellera eyes record IPO
Amanda Barrell explores how a perfect storm of changing economics, advances in technology, and the increasing volume of the patient voice is stoking change in the rare disease space. New models of drug development are fuelling life-changing advantages in the rare disease space, previously an… Read More »How the rare disease community has developed fertile ground for progress
BioNTech may be deeply ensconced in the latter stages of its bid to bring a COVID-19 vaccine to market, but it’s still pushing forward on other fronts, including a partnership with InstaDeep to deploy artificial intelligence and machine learning across its business. The two companies… Read More »BioNTech, InstaDeep plan joint lab for AI research
Front row (left to right): Jian Chen, Vice President, Xian Janssen Pharmaceuticals; Dan Wang, Head, Johnson & Johnson Innovation, Asia Pacific; Sharona Tao, Leader, Communications & Public Affairs, Johnson & Johnson China; Jennifer Yang, Head, Lung Cancer Initiative China, Johnson & Johnson Back row (left… Read More »Johnson & Johnson Innovation Launches 3 Collaborations to Advance Healthcare in China
What You Should Know: – Mission Bio launches industry’s first and only single-cell multi-omics platform, is announcing the launch of its most comprehensive instrument to-date, to save the industry billions of dollars in drug development costs and bring life-saving treatments to market at least six… Read More »Mission Bio Launches Single-Cell Multi-Omics System for Precision Cancer Therapies
insitro has landed another big biopharma partnership, signing a five-year collaboration with Bristol Myers Sqibb to develop therapies for amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Neurodegenerative disorders such as ALS and FTD are considered a challenging therapeutic area, with no disease modifying treatments… Read More »BMS joins forces with insitro to develop neurodegenerative treatments
What You Should Know: – The U.S. government’s Joint Pathology Center, which houses the world’s largest human tissue repository, today announced that Proscia, a leading digital and AI pathology company, will provide end-to-end modernization of JPC’s pathology operations. – The multi-phase project will digitize the… Read More »JPC Taps Proscia to Modernize World’s Largest Human Tissue Repository
While the definition of real world evidence is still evolving, most proponents associate it with data that is derived from medical practice among heterogeneous sets of patients in the real world setting. It is the integration of data gathered from various sources, such as EHRs,… Read More »REAL-WORLD EVIDENCE: THE GAME CHANGER IN DRUG DEVELOPMENT
Shots: Genesis to receive an up front and is eligible to receive pre/ clinical and regulatory milestones along with royalties on sales of approved drugs emerges from the collaboration The collaboration leverages Genesis’ graph machine learning and drug discovery expertise to identify drug candidates for… Read More »Roche Collaborates with Genesis Therapeutics for AI-Driven Drug Discovery
The deal with Roche subsidiary Genentech is likely not the last for Genesis Therapeutics, which is based on AI research undertaken at Stanford. Such partnerships are potentially lucrative for drug-discovery startups.
DNA-encoded libraries (DELs) have been gaining a lot of traction in hit finding and drug discovery in recent years. Regarded by some as a truly revolutionary advance in chemistry, a DEL is a mixture of millions of small molecules in which each molecule is conjugated… Read More »How DNA-encoded Libraries Boost Drug Discovery
Renee Yao, Global Healthcare AI Startups Lead at NVIDIA COVID-19 has put a tremendous burden on hospitals, and the clinicians, nurses, and medical staff who make them run. Many hospitals have suffered financially as they did not anticipate the severity of the disease. The extended… Read More »4 Areas Driving AI Adoption in Hospital Operations and Patient Safety
The six-year-old Google-backed company was founded by three MIT physicists and hopes to use its technology to make drug discovery faster and less cumbersome by combining physics, AI and cloud computing.
What You Should Know: – Repurpose.AI, has partnered with Scripps Research to discover drug candidates that may be repurposed to treat COVID-19. – The partnership will leverage Repurpose.AI’s ActivPred AI Drug Discovery Platform, an unbiased drug, target, and disease agnostic digital chemistry engine, to discover… Read More »Scripps Research, Repurpose.AI Partner to Develop COVID-19 Therapeutics
Increasing Rate of Drug Failure has Prompted the Drug Developers to Rely on CROs offering In Vitro ADME Testing Services for their Outsourcing Requirements
It is important to note that the process of drug discovery is extremely demanding, both in terms of capital and time. In fact, the overall amount spent on R&D initiatives in the pharmaceutical / biotechnology sector has increased from around USD 128 billion in 2008… Read More »Increasing Rate of Drug Failure has Prompted the Drug Developers to Rely on CROs offering In Vitro ADME Testing Services for their Outsourcing Requirements
Rising Popularity of Drug Targeting Synthetically Lethal Targets Fuels the Battle of PARP Inhibitors for Treatment of Advanced Cancer Indications
Cancer is considered to be the second leading cause of mortality, after cardiovascular diseases, accounting for every sixth reported death in the world. The International Agency for Research on Cancer (IARC) states that the number of new cancer cases is expected to grow to 27.5… Read More »Rising Popularity of Drug Targeting Synthetically Lethal Targets Fuels the Battle of PARP Inhibitors for Treatment of Advanced Cancer Indications
The concept of targeted protein degradation presents revolutionary drug development opportunities and is anticipated to bring about a paradigm shift in modern healthcare. While conventional medicines, such as small molecule inhibitors and monoclonal antibodies, address fewer than 20% of the proteome, targeted protein degradation offers… Read More »Targeted Protein Degradation – Defining a New Frontier in the Field of Medicine
Over time, the complexities associated with drug discovery have increased, especially in case of large molecule drugs, which are inherently more complex than conventional small molecules. As a result, an increase in the overall research and development (R&D) expenditure in the pharmaceutical / biotechnology sector… Read More »In Silico / Computer-Aided Drug Discovery Service Providers for Large Molecules